Johannes Krämer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Johannes Krämer has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
Christoph Wanner
Department of Internal Medicine I, Divisions of Cardiology and Nephrology, Comprehensive Heart Failure Center, Fabry Center for Interdisciplinary Therapy (FAZIT), University Hospital and University of Würzburg, Würzburg, Germany
11 shared publicationsGeorg Ertl
Medizinische Klinik I, University Hospital Würzburg, and Comprehensive Heart Failure Center, Würzburg, Germany
6 shared publicationsStefan Störk
Department of Internal Medicine I, Divisions of Cardiology and Nephrology, Comprehensive Heart Failure Center, Fabry Center for Interdisciplinary Therapy (FAZIT), University Hospital and University of Würzburg, Würzburg, Germany
6 shared publications- Frank Weidemann
Department of Medicine, Divisions of Cardiology and Nephrology, Comprehensive Heart Failure Center, Fabry Center for Interdisciplinary Therapy, University of Wurzburg, Wurzburg, Germany
5 shared publications - Eva Brand
Department of Internal Medicine D, and Interdisciplinary Fabry Center (IFAZ), University Hospital Muenster, Muenster, Germany
4 shared publications Frank Weidemann
Department of Internal Medicine I, Divisions of Cardiology and Nephrology, Comprehensive Heart Failure Center, Fabry Center for Interdisciplinary Therapy (FAZIT), University Hospital and University of Würzburg, Würzburg, Germany
4 shared publications
Latest Publications
- 28 October 2021
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 52 (S 01) , FV3.06
The Biochemical High Excreter Phenotype Is the Major Risk Factor for Cognitive Impairment in Early Diagnosed Individuals with Glutaric Aciduria Type 1
Background: Glutaric aciduria type 1 (GA1) is a rare inherited neurometabolic disorder. Both biochemical subtypes, i.e., high and low excreter share the same risk for severe movement disorder if untreated. Implementation into national newborn screening programs dramatically improved neurologic outcome, but cognitive functions have not systematically been studied. Methods: This national prospective observational study includes 107 individuals with confirmed GA1 identified by newborn screening between 1999 and 2020 in Germany. Standardized cognitive tests were used to evaluate clinical and cognitive (development and IQ) outcome. Results: Median age of 72 patients with at least one cognitive test was 7.9 years. Global development was normal in the majority of younger patients (15 of 24 [63%]; age range: 0.6–5.6 years). Isolated or global deficits were more frequent in patients with movement disorder (7 of 9 patients [78%]). Older patients with IQ tests (n = 56; age range: 3.4–19.1) showed significantly lower results than general population (median IQ: 87; interquartile range [IQR]: 78–98) which was more pronounced in individuals with high excreter phenotype (median IQ: 84; IQR: 75–96) than in low excreter patients (median IQ: 98; IQR: 92–105; p = 0.0164). Results were stable with age and homogenous on subscale level. Cognitive outcome was not impacted by sex, motor function, and quality of metabolic treatment. Conclusion: In GA1, neurologic long-term impairment involves both motor and cognitive function. Cognition is impacted by biochemical phenotype, but not by current therapy and striatal damage, implicating the necessity of more effective long-term treatment concepts, especially for high excreting patients. Publication Date: 28 October 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 28 October 2021
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 52 (S 01) , FV3.06
The Biochemical High Excreter Phenotype Is the Major Risk Factor for Cognitive Impairment in Early Diagnosed Individuals with Glutaric Aciduria Type 1
Background: Glutaric aciduria type 1 (GA1) is a rare inherited neurometabolic disorder. Both biochemical subtypes, i.e., high and low excreter share the same risk for severe movement disorder if untreated. Implementation into national newborn screening programs dramatically improved neurologic outcome, but cognitive functions have not systematically been studied. Methods: This national prospective observational study includes 107 individuals with confirmed GA1 identified by newborn screening between 1999 and 2020 in Germany. Standardized cognitive tests were used to evaluate clinical and cognitive (development and IQ) outcome. Results: Median age of 72 patients with at least one cognitive test was 7.9 years. Global development was normal in the majority of younger patients (15 of 24 [63%]; age range: 0.6–5.6 years). Isolated or global deficits were more frequent in patients with movement disorder (7 of 9 patients [78%]). Older patients with IQ tests (n = 56; age range: 3.4–19.1) showed significantly lower results than general population (median IQ: 87; interquartile range [IQR]: 78–98) which was more pronounced in individuals with high excreter phenotype (median IQ: 84; IQR: 75–96) than in low excreter patients (median IQ: 98; IQR: 92–105; p = 0.0164). Results were stable with age and homogenous on subscale level. Cognitive outcome was not impacted by sex, motor function, and quality of metabolic treatment. Conclusion: In GA1, neurologic long-term impairment involves both motor and cognitive function. Cognition is impacted by biochemical phenotype, but not by current therapy and striatal damage, implicating the necessity of more effective long-term treatment concepts, especially for high excreting patients. Publication Date: 28 October 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 12 October 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1
Publisher Correction: The biochemical subtype is a predictor for cognitive function in glutaric aciduria type 1: a national prospective follow-up study
- 12 October 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1
Open AccessPublisher Correction: The biochemical subtype is a predictor for cognitive function in glutaric aciduria type 1: a national prospective follow-up study
- Open Access
- 12 March 2019
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 7, 65
Heart Rate Response During Treadmill Exercise Test in Children and Adolescents With Congenital Heart Disease
Background: Impaired exercise capacity is a common feature of congenital heart disease (CHD). In adults with CHD, it has been shown that impaired heart rate response during exercise may contribute to exercise limitation. Systematic data in children and adolescents on this topic is limited. We therefore purposed to assess heart rate response during treadmill exercise testing in children and adolescents with CHD compared to healthy controls. Methods: One hundred and sixty three children and adolescents (103 with CHD, median age 15 years and 60 age-matched controls) performed cardiopulmonary exercise testing and were included in this study. Beyond peak oxygen consumption, increase in heart rate from resting level to peak exercise (heart rate reserve) and decrease of heart rate after peak exercise (heart rate recovery) were measured. Chronotropic index was defined as percentage of age predicted maximal heart rate reserve. According to data from adults on bicycle exercise, chronotropic incompetence was assumed for chronotropic index below 0.8. Results: While resting heart rate was similar between both groups, peak heart rate, heart rate reserve as well as chronotropic index were lower in the CHD group than in controls. Chronotropic index was lowest in patients with single ventricle hemodynamics and correlated with peak oxygen consumption. Heart rate recovery was impaired in the CHD group 1 and 2 min after peak exercise compared to controls and correlated with peak oxygen consumption. Chronotropic index below 0.8 was a relatively frequent finding even in the control group suggesting that the threshold of 0.8 appears inadequate for the identification of chronotropic incompetence using treadmill exercise testing in children. After normalizing to the 2.5th chronotropic index percentile of the control group we obtained a chronotropic incompetence threshold of 0.69. Conclusion: As an adjunct to measurement of peak oxygen consumption, heart rate response to exercise appears to be a physiologically important diagnostic parameter in children and adolescents with CHD. However, interpretation of heart rate response needs to consider specific age characteristics and the mode of exercise test. Our data may help future studies on chronotropic incompetence using treadmill ergometer protocols in children and adolescents.
- 12 March 2019
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 7, 65
Open AccessHeart Rate Response During Treadmill Exercise Test in Children and Adolescents With Congenital Heart Disease
Background: Impaired exercise capacity is a common feature of congenital heart disease (CHD). In adults with CHD, it has been shown that impaired heart rate response during exercise may contribute to exercise limitation. Systematic data in children and adolescents on this topic is limited. We therefore purposed to assess heart rate response during treadmill exercise testing in children and adolescents with CHD compared to healthy controls. Methods: One hundred and sixty three children and adolescents (103 with CHD, median age 15 years and 60 age-matched controls) performed cardiopulmonary exercise testing and were included in this study. Beyond peak oxygen consumption, increase in heart rate from resting level to peak exercise (heart rate reserve) and decrease of heart rate after peak exercise (heart rate recovery) were measured. Chronotropic index was defined as percentage of age predicted maximal heart rate reserve. According to data from adults on bicycle exercise, chronotropic incompetence was assumed for chronotropic index below 0.8. Results: While resting heart rate was similar between both groups, peak heart rate, heart rate reserve as well as chronotropic index were lower in the CHD group than in controls. Chronotropic index was lowest in patients with single ventricle hemodynamics and correlated with peak oxygen consumption. Heart rate recovery was impaired in the CHD group 1 and 2 min after peak exercise compared to controls and correlated with peak oxygen consumption. Chronotropic index below 0.8 was a relatively frequent finding even in the control group suggesting that the threshold of 0.8 appears inadequate for the identification of chronotropic incompetence using treadmill exercise testing in children. After normalizing to the 2.5th chronotropic index percentile of the control group we obtained a chronotropic incompetence threshold of 0.69. Conclusion: As an adjunct to measurement of peak oxygen consumption, heart rate response to exercise appears to be a physiologically important diagnostic parameter in children and adolescents with CHD. However, interpretation of heart rate response needs to consider specific age characteristics and the mode of exercise test. Our data may help future studies on chronotropic incompetence using treadmill ergometer protocols in children and adolescents.
- 7 May 2018
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 25 (13) , 1530-1537
Biomarkers for Diagnosing and Staging of Fabry Disease
Background: Fabry disease is a X-linked lysosomal storage disorder caused by deficient activity of α -galactosidase A which leads to progressive intracellular accumulation of globotriaosylceramide in tissues and organs including heart, kidney, vascular endothelium, the nervous system, the eyes and the skin. Cardiac involvement is common, leads to fatal complications and is mainly responsible for reduced life expectancy in Fabry disease. The exact staging of disease progression and timely initiation of treatment is essential in Fabry disease. Therefore it is essential to use the possibilities of specific biomarkers for early detection of organ involvement or early diagnosis. Methods: By the use of Pubmed all relevant papers for biomarkers in Fabry disease were screened. The quality of retrieved papers was appraised using standard tools. Finally 56 peer reviewed paper were included. Results: In the past biomarkers for Fabry disease biomarkers did not have clinical relevance. Nowadays, a lot of research is focusing on identification of new biomarkers and their clinical relevance. Only two biomarkers reached clinical applicability. Lyso-GB3 for identification of atypical FD variants and hsTNT for identification of cardiac involvement, which should indicate further diagnostics. Treatment response to ERT can be monitored by lyso-GB3 but data for long-time outcome are missing. A lot of GB3-related analogues are identified in urine and plasma, some of which might play an important role for managing Fabry disease in future. Conclusion: In conclusion, we suggest to measure lyso-GB3 and hsTNT at least once a year. The routinely measurement of these two biomarkers will help now for the staging of every individual patient and in addition, will help for a better general understanding of Fabry disease .
- 7 May 2018
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 25 (13) , 1530-1537
Biomarkers for Diagnosing and Staging of Fabry Disease
Background: Fabry disease is a X-linked lysosomal storage disorder caused by deficient activity of α -galactosidase A which leads to progressive intracellular accumulation of globotriaosylceramide in tissues and organs including heart, kidney, vascular endothelium, the nervous system, the eyes and the skin. Cardiac involvement is common, leads to fatal complications and is mainly responsible for reduced life expectancy in Fabry disease. The exact staging of disease progression and timely initiation of treatment is essential in Fabry disease. Therefore it is essential to use the possibilities of specific biomarkers for early detection of organ involvement or early diagnosis. Methods: By the use of Pubmed all relevant papers for biomarkers in Fabry disease were screened. The quality of retrieved papers was appraised using standard tools. Finally 56 peer reviewed paper were included. Results: In the past biomarkers for Fabry disease biomarkers did not have clinical relevance. Nowadays, a lot of research is focusing on identification of new biomarkers and their clinical relevance. Only two biomarkers reached clinical applicability. Lyso-GB3 for identification of atypical FD variants and hsTNT for identification of cardiac involvement, which should indicate further diagnostics. Treatment response to ERT can be monitored by lyso-GB3 but data for long-time outcome are missing. A lot of GB3-related analogues are identified in urine and plasma, some of which might play an important role for managing Fabry disease in future. Conclusion: In conclusion, we suggest to measure lyso-GB3 and hsTNT at least once a year. The routinely measurement of these two biomarkers will help now for the staging of every individual patient and in addition, will help for a better general understanding of Fabry disease .
- 14 March 2018
- Published by Springer Nature in Pediatric Cardiology
- Vol. 39 (6) , 1115-1122
Impact of the Right Ventricular Sokolow–Lyon Index in Children with Idiopathic Pulmonary Arterial Hypertension
Right ventricular (RV) hypertrophy is regarded as the adaptation on chronic RV pressure load in pulmonary hypertension. As the RV Sokolow–Lyon index (RVSLI) is an electrocardiographic marker of RV hypertrophy, we hypothesized that RVSLI might be able to reflect RV pressure load. Therefore, the purpose of this study was to characterize the diagnostic impact of the RVSLI in children with idiopathic pulmonary arterial hypertension (IPAH) in order to assess disease severity and to evaluate its value for the prediction of worse outcome. Forty-two children (aged 3–17 years) with IPAH were included in this retrospective study. The follow-up after baseline examination was 59 ± 17 months. Receiver-operating characteristic (ROC) curves and Kaplan–Meier analysis were used to discriminate a cut-off value of RVSLI and to assess its predictive value regarding morbidity and mortality. In 12/42 patients (29%) severe cardiovascular events (defined as death, lung transplantation, or Potts shunt) were observed (time to event 20 ± 22 months). Patients with an event showed higher RVSLI values (3.6 ± 1.2 mV vs. 2.6 ± 1.6 mV; p < 0.05). ROC analysis discriminated an RVSLI of 2.1 as the best cut-off value (area under the ROC curve: 0.79, sensitivity: 0.91, specificity: 0.70, p < 0.05) to detect patients with high-risk PAH (mPAP/mSAP ratio > 0.75). Relative risk for a severe event with an index > 2.1 mV was 1.76 (95% CI 1.21–3.20). Relative risk for death with RVSLI > 2.1 mV was 2.01 (95% CI 1.61–4.80). Our study demonstrates a strong relationship between RVSLI and disease severity in children with IPAH. An RVSLI > 2.1 mV at the time of first diagnosis is a predictor for patients at risk for cardiac events. As an adjunct to the usual diagnostic assessment this parameter may therefore contribute to the initial prognostic estimation.
- 14 March 2018
- Published by Springer Nature in Pediatric Cardiology
- Vol. 39 (6) , 1115-1122
Impact of the Right Ventricular Sokolow–Lyon Index in Children with Idiopathic Pulmonary Arterial Hypertension
Right ventricular (RV) hypertrophy is regarded as the adaptation on chronic RV pressure load in pulmonary hypertension. As the RV Sokolow–Lyon index (RVSLI) is an electrocardiographic marker of RV hypertrophy, we hypothesized that RVSLI might be able to reflect RV pressure load. Therefore, the purpose of this study was to characterize the diagnostic impact of the RVSLI in children with idiopathic pulmonary arterial hypertension (IPAH) in order to assess disease severity and to evaluate its value for the prediction of worse outcome. Forty-two children (aged 3–17 years) with IPAH were included in this retrospective study. The follow-up after baseline examination was 59 ± 17 months. Receiver-operating characteristic (ROC) curves and Kaplan–Meier analysis were used to discriminate a cut-off value of RVSLI and to assess its predictive value regarding morbidity and mortality. In 12/42 patients (29%) severe cardiovascular events (defined as death, lung transplantation, or Potts shunt) were observed (time to event 20 ± 22 months). Patients with an event showed higher RVSLI values (3.6 ± 1.2 mV vs. 2.6 ± 1.6 mV; p < 0.05). ROC analysis discriminated an RVSLI of 2.1 as the best cut-off value (area under the ROC curve: 0.79, sensitivity: 0.91, specificity: 0.70, p < 0.05) to detect patients with high-risk PAH (mPAP/mSAP ratio > 0.75). Relative risk for a severe event with an index > 2.1 mV was 1.76 (95% CI 1.21–3.20). Relative risk for death with RVSLI > 2.1 mV was 2.01 (95% CI 1.61–4.80). Our study demonstrates a strong relationship between RVSLI and disease severity in children with IPAH. An RVSLI > 2.1 mV at the time of first diagnosis is a predictor for patients at risk for cardiac events. As an adjunct to the usual diagnostic assessment this parameter may therefore contribute to the initial prognostic estimation.
- Open Access
- 1 January 2018
- Published by Dissolution Technologies in Dissolution Technologies
- Vol. 25 (3) , 64-69
In Vitro Performance Testing of Medicated Chewing Gums
- 1 January 2018
- Published by Dissolution Technologies in Dissolution Technologies
- Vol. 25 (3) , 64-69
Open AccessIn Vitro Performance Testing of Medicated Chewing Gums
- 23 November 2017
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (8) , 1362-1372
Fabry disease under enzyme replacement therapy—new insights in efficacy of different dosages
Fabry patients on reduced dose of agalsidase-beta or after switch to agalsidase-alfa show a decline in estimated glomerular filtration rate (eGFR) and an increase of the Mainz Severity Score Index. In this prospective observational study, we assessed end-organ damage and clinical symptoms in 112 patients who had received agalsidase-beta (1.0 mg/kg) for >1 year, who were (i) non-randomly assigned to continue this treatment regime (regular-dose group, n = 37); (ii) received a reduced dose of agalsidase-beta and subsequent switch to agalsidase-alfa (0.2 mg/kg) or a direct switch to 0.2 mg/kg agalsidase-alfa (switch group, n = 38); or (iii) were re-switched to agalsidase-beta after receiving agalsidase-alfa for at least 12 months (re-switch group, n = 37) with a median follow-up of 53 (38–57) months. eGFR of patients in the regular-dose group remained stable. Patients in the switch group showed an annual eGFR loss of − 4.6 ± 9.1 mL/min/1.73 m2 (P < 0.05). Patients in the re-switch group also had an eGFR loss of − 2.2 ± 4.4 mL/min/1.73 m2 after re-switch to agalsidase-beta, but to a lower degree compared with the switch group (P < 0.05). Patients in the re-switch group suffered less frequently from diarrhoea (relative risk 0.42; 95% confidence interval 0.19–0.93; P = 0.02). Lyso-Gb3 remained stable in the switch (P = 0.97) and the regular-dose (P = 0.48) groups, but decreased in the re-switch group after change of the therapy regimen (P < 0.05). After switch to agalsidase-alfa, Fabry patients experienced a continuous decline in eGFR, while this decline was attenuated in patients who were re-switched to agalsidase-beta. Decreasing lyso-Gb3 levels may indicate a better treatment response in the latter group.
- 23 November 2017
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (8) , 1362-1372
Fabry disease under enzyme replacement therapy—new insights in efficacy of different dosages
Fabry patients on reduced dose of agalsidase-beta or after switch to agalsidase-alfa show a decline in estimated glomerular filtration rate (eGFR) and an increase of the Mainz Severity Score Index. In this prospective observational study, we assessed end-organ damage and clinical symptoms in 112 patients who had received agalsidase-beta (1.0 mg/kg) for >1 year, who were (i) non-randomly assigned to continue this treatment regime (regular-dose group, n = 37); (ii) received a reduced dose of agalsidase-beta and subsequent switch to agalsidase-alfa (0.2 mg/kg) or a direct switch to 0.2 mg/kg agalsidase-alfa (switch group, n = 38); or (iii) were re-switched to agalsidase-beta after receiving agalsidase-alfa for at least 12 months (re-switch group, n = 37) with a median follow-up of 53 (38–57) months. eGFR of patients in the regular-dose group remained stable. Patients in the switch group showed an annual eGFR loss of − 4.6 ± 9.1 mL/min/1.73 m2 (P < 0.05). Patients in the re-switch group also had an eGFR loss of − 2.2 ± 4.4 mL/min/1.73 m2 after re-switch to agalsidase-beta, but to a lower degree compared with the switch group (P < 0.05). Patients in the re-switch group suffered less frequently from diarrhoea (relative risk 0.42; 95% confidence interval 0.19–0.93; P = 0.02). Lyso-Gb3 remained stable in the switch (P = 0.97) and the regular-dose (P = 0.48) groups, but decreased in the re-switch group after change of the therapy regimen (P < 0.05). After switch to agalsidase-alfa, Fabry patients experienced a continuous decline in eGFR, while this decline was attenuated in patients who were re-switched to agalsidase-beta. Decreasing lyso-Gb3 levels may indicate a better treatment response in the latter group.
- Open Access
- 29 June 2016
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 11 (1) , 1-11
Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease
The aim of the present study was to assess manifestations of and applied treatment concepts for females with Fabry disease (FD) according to the current European Fabry Guidelines. Between 10/2008 and 12/2014, data from the most recent visit of 261 adult female FD patients from six German Fabry centers were retrospectively analyzed. Clinical presentation and laboratory data, including plasma lyso-Gb3 levels were assessed. Fifty-five percent of females were on enzyme replacement therapy (ERT), according to recent European FD guidelines. Thirty-three percent of females were untreated although criteria for ERT initiation were fulfilled. In general, the presence of left ventricular hypertrophy (LVH) seemed to impact more on ERT initiation than impaired renal function. In ERT-naïve females RAAS blockers were more often prescribed if LVH was present rather than albuminuria. Affected females with missense mutations showed a similar disease burden compared to females with nonsense mutations. Elevated plasma lyso-Gb3 levels in ERT-naïve females seem to be a marker of disease burden, since patients showed comparable incidences of organ manifestations even if they were ~8 years younger than females with normal lyso-Gb3 levels. The treatment of the majority of females with FD in Germany is in line with the current European FD guidelines. However, a relevant number of females remain untreated despite organ involvement, necessitating a careful reevaluation of these females.
- 29 June 2016
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 11 (1) , 1-11
Open AccessMulticenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease
The aim of the present study was to assess manifestations of and applied treatment concepts for females with Fabry disease (FD) according to the current European Fabry Guidelines. Between 10/2008 and 12/2014, data from the most recent visit of 261 adult female FD patients from six German Fabry centers were retrospectively analyzed. Clinical presentation and laboratory data, including plasma lyso-Gb3 levels were assessed. Fifty-five percent of females were on enzyme replacement therapy (ERT), according to recent European FD guidelines. Thirty-three percent of females were untreated although criteria for ERT initiation were fulfilled. In general, the presence of left ventricular hypertrophy (LVH) seemed to impact more on ERT initiation than impaired renal function. In ERT-naïve females RAAS blockers were more often prescribed if LVH was present rather than albuminuria. Affected females with missense mutations showed a similar disease burden compared to females with nonsense mutations. Elevated plasma lyso-Gb3 levels in ERT-naïve females seem to be a marker of disease burden, since patients showed comparable incidences of organ manifestations even if they were ~8 years younger than females with normal lyso-Gb3 levels. The treatment of the majority of females with FD in Germany is in line with the current European FD guidelines. However, a relevant number of females remain untreated despite organ involvement, necessitating a careful reevaluation of these females.
- Open Access
- 13 June 2016
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 5 (6) , e002839
High‐Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease
Background: High‐sensitivity troponin (hs‐ TNT ), a biomarker of myocardial damage, might be useful for assessing fibrosis in Fabry cardiomyopathy. We performed a prospective analysis of hs‐ TNT as a biomarker for myocardial changes in Fabry patients and a retrospective longitudinal follow‐up study to assess longitudinal hs‐ TNT changes relative to fibrosis and cardiomyopathy progression. Methods and Results: For the prospective analysis, hs‐ TNT from 75 consecutive patients with genetically confirmed Fabry disease was analyzed relative to typical Fabry‐associated echocardiographic findings and total myocardial fibrosis as measured by late gadolinium enhancement ( LE ) on magnetic resonance imaging. Longitudinal data (3.9±2.0 years), including hs‐ TNT , LE , and echocardiographic findings from 58 Fabry patients, were retrospectively collected. Hs‐ TNT level positively correlated with LE (linear correlation coefficient, 0.72; odds ratio, 32.81 [95% CI, 3.56–302.59]; P =0.002); patients with elevated baseline hs‐ TNT (>14 ng/L) showed significantly increased LE (median: baseline, 1.9 [1.1–3.3] %; follow‐up, 3.2 [2.3–4.9] %; P P =0.116) during follow‐up. Left ventricular wall thickness and EF of patients with elevated hs‐ TNT were decreased during follow‐up, indicating potential cardiomyopathy progression. Conclusions: hs‐ TNT is an accurate, easily accessible clinical blood biomarker for detecting replacement fibrosis in patients with Fabry disease and a qualified predictor of cardiomyopathy progression. Thus, hs‐ TNT could be helpful for staging and follow‐up of Fabry patients.
- 13 June 2016
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 5 (6) , e002839
Open AccessHigh‐Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease
Background: High‐sensitivity troponin (hs‐ TNT ), a biomarker of myocardial damage, might be useful for assessing fibrosis in Fabry cardiomyopathy. We performed a prospective analysis of hs‐ TNT as a biomarker for myocardial changes in Fabry patients and a retrospective longitudinal follow‐up study to assess longitudinal hs‐ TNT changes relative to fibrosis and cardiomyopathy progression. Methods and Results: For the prospective analysis, hs‐ TNT from 75 consecutive patients with genetically confirmed Fabry disease was analyzed relative to typical Fabry‐associated echocardiographic findings and total myocardial fibrosis as measured by late gadolinium enhancement ( LE ) on magnetic resonance imaging. Longitudinal data (3.9±2.0 years), including hs‐ TNT , LE , and echocardiographic findings from 58 Fabry patients, were retrospectively collected. Hs‐ TNT level positively correlated with LE (linear correlation coefficient, 0.72; odds ratio, 32.81 [95% CI, 3.56–302.59]; P =0.002); patients with elevated baseline hs‐ TNT (>14 ng/L) showed significantly increased LE (median: baseline, 1.9 [1.1–3.3] %; follow‐up, 3.2 [2.3–4.9] %; P P =0.116) during follow‐up. Left ventricular wall thickness and EF of patients with elevated hs‐ TNT were decreased during follow‐up, indicating potential cardiomyopathy progression. Conclusions: hs‐ TNT is an accurate, easily accessible clinical blood biomarker for detecting replacement fibrosis in patients with Fabry disease and a qualified predictor of cardiomyopathy progression. Thus, hs‐ TNT could be helpful for staging and follow‐up of Fabry patients.
- Open Access
- 4 May 2016
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 11 (1) , 54
Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant
Fabry disease (FD) is an X-linked multisystemic disorder with a heterogeneous phenotype. Especially atypical or late-onset type 2 phenotypes present a therapeutical dilemma. To determine the clinical impact of the alpha-Galactosidase A (GLA) p.A143T/ c.427G > A variation, we retrospectively analyzed 25 p.A143T patients in comparison to 58 FD patients with other missense mutations. p.A143T patients suffering from stroke/ transient ischemic attacks had slightly decreased residual GLA activities, and/or increased lyso-Gb3 levels, suspecting FD. However, most male p.A143T patients presented with significant residual GLA activity (~50 % of reference), which was associated with normal lyso-Gb3 levels. Additionally, p.A143T patients showed less severe FD-typical symptoms and absent FD-typical renal and cardiac involvement in comparison to FD patients with other missense mutations. Two tested female p.A143T patients with stroke/TIA did not show skewed X chromosome inactivation. No accumulation of neurologic events in family members of p.A143T patients with stroke/transient ischemic attacks was observed. We conclude that GLA p.A143T seems to be most likely a neutral variant or a possible modifier instead of a disease-causing mutation. Therefore, we suggest that p.A143T patients with stroke/transient ischemic attacks of unknown etiology should be further evaluated, since the diagnosis of FD is not probable and subsequent ERT or chaperone treatment should not be an unreflected option.
- 4 May 2016
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 11 (1) , 54
Open AccessAlpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant
Fabry disease (FD) is an X-linked multisystemic disorder with a heterogeneous phenotype. Especially atypical or late-onset type 2 phenotypes present a therapeutical dilemma. To determine the clinical impact of the alpha-Galactosidase A (GLA) p.A143T/ c.427G > A variation, we retrospectively analyzed 25 p.A143T patients in comparison to 58 FD patients with other missense mutations. p.A143T patients suffering from stroke/ transient ischemic attacks had slightly decreased residual GLA activities, and/or increased lyso-Gb3 levels, suspecting FD. However, most male p.A143T patients presented with significant residual GLA activity (~50 % of reference), which was associated with normal lyso-Gb3 levels. Additionally, p.A143T patients showed less severe FD-typical symptoms and absent FD-typical renal and cardiac involvement in comparison to FD patients with other missense mutations. Two tested female p.A143T patients with stroke/TIA did not show skewed X chromosome inactivation. No accumulation of neurologic events in family members of p.A143T patients with stroke/transient ischemic attacks was observed. We conclude that GLA p.A143T seems to be most likely a neutral variant or a possible modifier instead of a disease-causing mutation. Therefore, we suggest that p.A143T patients with stroke/transient ischemic attacks of unknown etiology should be further evaluated, since the diagnosis of FD is not probable and subsequent ERT or chaperone treatment should not be an unreflected option.